Compare BridgeBio Pharma Inc (BBIO) vs Southwest Airlines Co (LUV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Southwest Airlines Co — how do they compare? BridgeBio Pharma Inc trades at $84.12 (market cap $16.46B), while Southwest Airlines Co trades at $47.75 (market cap $23.25B). The key difference: Southwest Airlines Co is the larger of the two by market cap, and Southwest Airlines Co pays a 1.51% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | LUV | |
|---|---|---|
Market Cap | $16.46B | $23.25B |
Sector | Health | Industrials |
52-Week High | $90.17 | $54.80 |
52-Week Low | $44.81 | $29.06 |
Enterprise Value | $18.02B | $26.31B |
Dividend Yield | — | 1.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
Southwest Airlines (LUV) trades at $47.92, down 1.05% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $52.47 suggesting upside. Recent earnings show a mix of beats and a miss, with Q2 2026 results expected soon. The company maintains a solid balance sheet with a debt-to-asset ratio improving to 16.86% in 2025, though net cash flow remains negative due to significant financing activities.
The outlook is cautiously optimistic, driven by potential earnings growth and cost management, but risks include fuel price volatility and competitive pressures. Analyst sentiment is mixed, with 42% buy ratings, highlighting both recovery potential and near-term headwinds for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Southwest Airlines Co
Southwest Airlines is the largest domestic carrier in the United States, as measured by the number of originating passengers boarded. Southwest operates over 700 aircraft in an all-Boeing 737 fleet. Despite expanding into longer routes and business travel, the airline still specializes in short-haul leisure flights, using a point-to-point network. Southwest operates a low-cost carrier business model.
Read more on LUV →
